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HIV-1 infection poses a public health problem 
that is partially controlled by a combination of 
specific antiretroviral agents. Nonetheless, the 
surge of multiresistant HIV-1 strains will require 
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Extracellular adenosine triphosphate (ATP) can activate purinergic receptors of the plasma 
membrane and modulate multiple cellular functions. We report that ATP is released from 
HIV-1 target cells through pannexin-1 channels upon interaction between the HIV-1 
envelope protein and specific target cell receptors. Extracellular ATP then acts on puriner-
gic receptors, including P2Y2, to activate proline-rich tyrosine kinase 2 (Pyk2) kinase and 
transient plasma membrane depolarization, which in turn stimulate fusion between Env-
expressing membranes and membranes containing CD4 plus appropriate chemokine co-
receptors. Inhibition of any of the constituents of this cascade (pannexin-1, ATP, P2Y2, and 
Pyk2) impairs the replication of HIV-1 mutant viruses that are resistant to conventional 
antiretroviral agents. Altogether, our results reveal a novel signaling pathway involved in 
the early steps of HIV-1 infection that may be targeted with new therapeutic approaches.
© 2011 Séror et al.  This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the 
publication date (see http://www.rupress.org/terms). After six months it is available 
under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Un-
ported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
the development of novel antiviral strategies.  Target-
ing early infection by vaccines and microbicides 
represents the main challenge to end the AIDS 
epidemic (Haase, 2010; Virgin and Walker, 2010). 
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osmotic swelling [Darby et al., 2003], and membrane shrink-
ing [Corriden and Insel, 2010]) stimulates ATP release. Ini-
tially described as a second messenger in the nervous and 
vascular systems (Schwiebert et al., 2002; Housley et al., 2009), 
extracellular ATP may also act as a proinflammatory mediator 
released during acute inflammation upon cell damage or bac-
terial infection, thus representing a generic marker of damage 
which can alert the immune system to danger (Gallucci and 
Matzinger, 2001). In addition, extracellular ATP inhibits in-
fection by intracellular bacterial pathogens (Lammas et al., 
1997; Coutinho-Silva et al., 2003) and modulates immune 
responses by participating in the chemotaxis of immune cells 
A better understanding of the early steps of HIV-1 infection 
is critical to achieving this goal. Enveloped viruses must fuse 
their membranes with host cell membranes to allow produc-
tive  infection.  Major  transient  changes  in  the  charge  and   
architecture of the host plasma membrane, including extreme 
curvature, occur during early steps of infection and facilitate 
viral replication (Miller et al., 1993; Davis et al., 2004). How-
ever, little is known about the consequences of these cell 
membrane alterations on the early signaling pathway required 
for viral infection.
Recent studies revealed that membrane stress induced by 
mechanical or chemical stimuli (shear stress [Wan et al., 2008], 
Figure 1.  ATP release through pannexin-1 
hemichannels modulates interactions of 
HIV-1 with target cells. (A) ATP released by 
CD4+CXCR4+ cells during HIVNL43 infection  
(MOI = 1; black circle) or in the absence of infec-
tion (white circle) was determined at different 
time points by ATP-dependent bioluminescence in   
three independent experiments. One represen-
tative experiment is shown (mean ± SEM of 
triplicates; *, P < 0.01). (B) CD4+CXCR4+ cells 
expressing a Tat-inducible -galactosidase  
(-gal) reporter gene were infected with HIVNL43 
(MOI = 1) during 48 h in the presence of differ-
ent concentrations of apyrase. Then, the me-
dium containing apyrase was removed, replaced 
by complete medium, and target cell infection 
was determined 48 h after infection (mean ± SEM; 
three independent experiments; *, P < 0.05).  
(C) ATP release was expressed as a fold  
increase of ATP release during co-culture of 
HIV-1 target cells with Env+ or Env cells. Error 
bars indicate SEM of three independent deter-
minations (*, P < 0.05). (D) Effect of ATP deple-
tion by apyrase on HIV-1 envelope mediated 
actin polymerization. Actin polymerization in 
pairs of interacting cells was determined in 
three independent experiments (means ± SEM; 
*, P < 0.05) by fluorescence microscopy. The 
inset illustrates actin polymerization (green) 
between an Env+ cell (red) and an interacting 
CD4+CXCR4+ cell (bar, 5 µm). (E) Localization of 
pannexin-1 at the contact site between primary 
HIV-1–infected lymphoblasts (green) and pri-
mary uninfected lymphoblasts, visualized by 
confocal microscopy. The arrowhead points to 
pannexin-1 accumulation (red) at the interface 
between primary infected and uninfected lymphoblasts (bar, 5 µm). A representative micrograph with merged images of xz (bar, 4 µm) and yz (bar, 1 µm) opti-
cal sections are shown. (F) Polarization of pannexin-1 (red) on the virological synapse between HIV-1–infected lymphoblasts (blue) and that of HIV-1–infected 
and uninfected cells. Arrowheads highlight the colocalization between pannexin-1 and the HIV-1 envelope glycoprotein gp41 (green; bar, 5 µm). The images in 
E and F are representative of at least 40 cells in three independent experiments. (G) CEM cells were infected during 6 d with HIVNL43 (MOI = 1) in the presence of 
different concentrations of DIDS or SITS. Effects on target cell survival and on p24 antigen release were determined. Error bars indicate SD of three independent 
determinations (*, P < 0.01; **, P < 0.001). (H) CD4+CXCR4+ cells expressing Tat-inducible -gal reporter gene were infected with HIVNL43 (MOI = 1) during 3 h in 
the presence of the indicated concentrations of the indicated inhibitors. The medium was removed, replaced by complete medium, and target cell infectivity 
was determined (means ± SEM; n = 3; *, P < 0.01). (I) CD4+CXCR4+ cells were transfected during 48 h with siRNAs specific for pannexin-1 or control siRNA and 
then infected with HIVNL43 (MOI = 1). Pannexin-1 mRNA expression was measured by quantitative real-time RT-PCR. The effect of pannexin-1 depletion on p24 
antigen release was determined as described in Materials and methods (means ± SEM; n = 3; *, P < 0.01; **, P < 0.001). (J and K) Cells were transfected with 
siRNA as in I. ATP release and HIV-1 infection were determined after 3 h (by ATP-dependent bioluminescence) and after 48 h (using CD4+CXCR4+ cells that 
contain a Tat-inducible -Gal reporter), respectively. Results were obtained in three independent experiments (mean ± SEM; *, P < 0.05).JEM Vol. 208, No. 9 
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(Fig. S1, A and D) prevented HIV-1 infection (Fig. 1 B), whereas 
supplementation with ATP or with its nonhydrolyzable analogue 
ATP-S did not enhance HIV-1 infection (Fig. S1, C and D), 
perhaps because local ATP release is already optimal in the prox-
imity of virions infecting cells. Co-culture of CD4+CXCR4+ 
cells with cells expressing the HIV-1 envelope glycoprotein com-
plex (Env) at the plasma membrane also caused ATP release 
(eosinophils, neutrophils, monocytes/macrophages, and im-
mature DCs; Chen et al., 2006; Kronlage et al., 2010), by acti-
vating the NALP3 inflammasome (Mariathasan et al., 2006), 
or by mediating costimulatory signals for antigenic stimula-
tion (Schenk et al., 2008). Recent studies revealed that ATP 
can also be released under basal conditions and influences a 
large array of cellular responses. Thus, ATP seems to act as an 
inside-out messenger that fine tunes signal transduction path-
ways (Corriden and Insel, 2010).
Outside of the cell, ATP acts as an autocrine/paracrine 
signal, modulating a variety of cellular functions by activating 
purinergic receptors (Corriden and Insel, 2010). These plasma 
membrane–localized receptors belong to a larger family that 
can be classified into ionotropic P2X receptor and metabo-
tropic P2Y receptors (Ralevic and Burnstock, 1998). Metabo-
tropic receptors are coupled to intracellular signaling pathways 
through heterotrimeric G proteins (Abbracchio et al., 2006), 
whereas ionotropic P2X receptors are associated with pores 
that open upon ATP binding, allowing Ca2+ influx and K+ 
efflux  (Ralevic  and  Burnstock,  1998).  Seven  members  of   
the  P2X  family  (P2X1–7;  Ralevic  and  Burnstock,  1998)   
and eight P2Y receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, 
P2Y12,  P2Y13,  and  P2Y14)  have  been  characterized   
(Abbracchio et al., 2003). Upon activation, these receptors, 
which are widely distributed throughout the body, modulate 
an array of cellular functions like plasma membrane perme-
abilization, Ca2+ influx, and cell death (Surprenant and North, 
2009). Purinergic receptors have been extensively involved in 
the development of innate and/or adaptive immune responses 
against pathogens (Lammas et al., 1997; Coutinho-Silva et al., 
2003; Chen et al., 2006; Mariathasan et al., 2006; Kronlage   
et al., 2010) but have also been associated with chemotherapy- 
driven anticancer immune responses (Ghiringhelli et al., 2009).
In this study, we determined whether ATP and purinergic 
receptors might modulate HIV-1 infection. We found that the 
HIV-encoded envelope glycoprotein complex (Env) can stim-
ulate the release of ATP from HIV-1 target cells and that   
extracellular ATP then stimulates purinergic signals that facili-
tate HIV-1 infection. We characterized several elements of the 
signal transduction pathway—which facilitates ATP release 
from HIV-1 target cells and mediates autocrine ATP effects— 
that are essential for the early steps of HIV-1 infection.
RESULTS
ATP release from target cells participates in HIV-1 infection
Because membrane stress can induce the release of ATP from 
mammalian cells (Corriden and Insel, 2010), we speculated that 
HIV-1 infection might trigger ATP release from host cells. We 
found  that  infection  of  human  cells  with  X4-tropic  HIV-1 
(HIVNL43), which relies on the expression of CD4 and CXCR4 
the receptor and co-receptor of HIV-1 (Dalgleish et al., 1984; 
Feng et al., 1996), led to rapid ATP release within the first 2 h of 
infection (Fig. 1 A). The depletion of CD4 by small interfering 
RNAs (siRNAs) or the inhibition of CXCR4 with its antago-
nist AMD3100 prevented ATP release (Fig. S1, A, B, E, and F). 
The addition of the nontoxic ATP-degrading enzyme apyrase 
Figure 2.  Purinergic receptors modulate HIV-1 infection. (A–C) Ef-
fects of CXCR4 receptor antagonist AMD3100 and the general P2 receptor 
antagonists suramin, PPADS, and OxATP on p24 release (A), host cell infec-
tivity (B), and hemifusion/fusion (C), as observed during infection of 
PHA+IL-2–stimulated human PBMCs with HIVNDK and HIVBaL (A), during 
infection of CD4+CXCR4+ cells with HIVNL43WT and HIVNL43Env (B), or during 
co-culture of Env+ cells with HIV-1 target cells (C). Columns in A–C show 
means ± SEM (n = 3; *, P < 0.05). (D and E) Effects of 5 µM AMD3100,  
10 UI/ml apyrase, 10 µM suramin, 100 µM PPADS, 100 µM OxATP, and  
500 nM efavirenz (Efav) on viral RNA expression and on total viral DNA 
expression of wild-type (HIVNL43WT) or VSVG pseudotyped (HIVNL43Env) HIV-1 
in CD4+CXCR4+ cells. Viral RNA was detected by quantitative PCR. Note 
that the internalization of pseudotyped HIVNL43Env virus was not reduced 
by these inhibitors (D). Total viral DNA was determined by PCR and results 
were normalized with respect to GAPDH (E). Efavirenz was used as an 
internal control of reverse transcription activity inhibition. The results are 
representative of three independent experiments.1826 ATP release boosts HIV-1 infectivity | Séror et al.
Pharmacological inhibition of pannexin-1 with 4,4 diiso-
thiocyanatostilbene-2,2-disulfonic acid (DIDS) or 4-acetamido-
4-isothiocyanatostilbene-2,2 disulfonic acid (SITS) protected 
target cells against HIV-1–induced cell death (Fig. 1 G),   
reduced p24 antigen release (Fig. 1 G), and inhibited HIV-1 
infection  and  fusion  between  CD4/CXCR4  and  Env- 
expressing cells (Fig. 1 H; and Fig. S1, J and K). In these 6-d-long 
experiments, DIDS and SITS inhibited HIV-1 infection at 
doses that are lower than those required to prevent fusion   
between HIV Env+ and CD4+CXCR4+ cells, perhaps re-
flecting cumulative effects over multiple viral cycles and/or 
distinct avidities (and hence susceptibilities to inhibition) of 
the interaction of infectable cells with HIV-1 Env present at 
the surface of cells versus viral particles. siRNA-mediated de-
pletion of pannexin-1 from HIV-1 target cells also decreased 
p24 antigen release (Fig. 1 I), reduced HIV-1 infection (Fig. 1 J), 
blocked HIV-1 Env–mediated fusion (Fig. S1 L), and inhib-
ited the release of ATP from host cells during conjugate for-
mation (Fig. S1 L) and HIV-1 infection (Fig. 1 K). Thus, 
extracellular ATP release plays a major role in Env-dependent 
interactions between HIV-1 and host cells.
Purinergic receptors contribute to viral uptake
Extracellular ATP constitutes a common danger signal that is 
sensed by distinct purinergic receptors (Khakh and North, 
2006). General inhibitors of purinergic receptors, including 
suramin, pyridoxal-phosphate-6-azophenyl-2,4-disulfonate 
(PPADS), and oxidized ATP (OxATP), blocked the replica-
tion of both X4-tropic HIV (e.g., HIVNDK) and R5-tropic 
HIV (e.g., HIVBaL) in activated T lymphoblasts (Fig. 2 A and 
Fig. S2 A). Purinergic receptor antagonists also blocked the 
replication  of  R5-tropic  HIV-1  in  macrophages  (Fig.  S2,   
B and C) or DCs (Fig. S2, D and E) and that of clinical HIV-1 
isolates in C8166 T leukemia cells (Fig. S2, F–H).
Cervical  epithelial  (HeLa)  cells  engineered  to  express 
CD4/CXCR4,  as  well  as  a Tat-inducible  -galactosidase   
(-Gal) reporter, expressed -Gal upon infection with a lym-
photropic  HIV-1  (HIVNL43WT).  Such  cells  also  expressed   
-Gal  upon  infection  by  an  isogenic  virus  in  which  the   
endogenous Env gene had been replaced by that of vesicular 
stomatitis virus (VSV; HIVNL43Env) allowing the virus to   
infect cells which lack CD4/CXCR4 (Reiser et al., 1996). 
Purinergic receptor antagonists were more efficient in inhib-
iting -Gal induction by Env-expressing than that by VSV-
pseudotyped HIV-1 (Fig. 2 B and Fig. S3 A), indicating that 
they mainly affect the receptor-dependent facet of HIV-1   
infection. Purinergic receptor inhibition also reduced the hem-
ifusion (which causes the exchange of fluorescent lipids between 
interacting cells) and cell-to-cell fusion (syncytium formation 
with  mixture  of  the  cytoplasm)  between  CD4+CXCR4+ 
cells and Env-expressing cells (Fig. 2 C and Fig. S3 B). Finally, 
purinergic receptor antagonists prevented the entry of HIV-1 
into cells, as revealed by their inhibitory effects on the detection 
of HIV genomes at the RNA (Fig. 2 D) and DNA (Fig. 2 E)   
levels within host cells. In contrast, purinergic receptor inhi-
bition did not affect the replication of VSV-pseudotyped 
as the cells were engaging in conjugates (Fig. 1 C). Apyrase 
abolished conjugate formation and the accompanying actin 
polymerization in juxtaposed cells (Fig. 1 D). The release of ATP 
from cells constitutes a common response to shear stress and   
osmotic imbalance (Wang et al., 2005) and can be mediated 
through mechanosensitive pannexin-1 hemichannels (Bao et al., 
2004). Indeed, pannexin-1 was enriched at the contact site be-
tween HIV-1–infected lymphoblasts (which express Env on the 
surface)  and  uninfected  lymphoblasts  (Fig.  1  E).  Pannexin-1   
polarization occurred in conditions in which the levels of   
pannexin-1 protein remained constant (Fig. S1 G) and was pref-
erentially detected in uninfected cells (Fig. S1, H and I). In addi-
tion, pannexin-1 was associated with virological synapses that 
formed between infected and uninfected cells (Fig. 1 F).
Figure 3.  Detection of P2Y2 expression during HIV-1 infection. 
(A–D) Immunohistochemical P2Y2 detection in lymph node biopsies  
(A) and frontal cortex biopsies (B) obtained from HIV-1–infected patients. 
The insets illustrate the absence of staining in lymph node and frontal 
cortex biopsies from uninfected patients (bars, 50 µm). The percentage of 
P2Y2+ cells was determined in lymph node (C) and frontal cortex (D) biop-
sies. Error bars represent means ± SEM (n = 5; *, P < 0.01). (E and F) P2Y2 
detection in PBMCs obtained from uninfected or untreated HIV-1–infected 
patients. Representative microphotographs are shown in E (bars, 20 µm) 
and quantitative data are shown in F (mean ± SEM; n = 3; *, P < 0.05).  
(G) Primary lymphoblasts were infected with HIVNDK (MOI=1) for the indi-
cated periods. Then P2Y2 expression was evaluated by immunoblotting. 
Representative immunoblots of three independent experiments are 
shown. (H) Expression of P2Y2 on PBMC () and on PHA+IL-2–activated 
PBMC was determined in three independent experiments and one repre-
sentative immunoblot is shown.JEM Vol. 208, No. 9 
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Env-triggered syncytium formation (Fig. S5 G). Immuno-
reactive P2Y2 was detectable at higher levels in lymphoid   
tissues (Fig. 3, A and C), in the frontal cortex (Fig. 3, B and D), 
and in circulating leukocytes (Fig. 3, E and F) from untreated 
HIV-1 carriers, as compared with uninfected carriers (Fig. 3, A, 
B, and E) and samples stained with isotype control antibody 
(Fig. S5, H and I). The levels of P2Y2 protein rapidly in-
creased during in vitro HIV-1 infection of human PBMCs 
(Fig. 3 G), or CD4+CXCR4+ HeLa cells (Fig. S5 J), as well as 
after stimulation of human PBMCs with PHA and IL-2   
(Fig. 3 H). Both HIV-1–infected and uninfected cells over-
expressed P2Y2 (Fig. S6 A). Immunofluorescence microscopy 
HIV-1 (Fig. 2, D and E). These results demonstrate that puri-
nergic receptors are critical for the Env-mediated internaliza-
tion of HIV-1 into suitable target cells.
Purinergic receptor P2Y2 modulates  
HIV-1 infection
To  identify  the  principal  purinergic  receptors  involved  in 
HIV-1  internalization,  we  determined  purinergic  receptor 
expression on HIV-1 target cells (Fig. S4, A–N) and we selec-
tively depleted the mRNAs coding for P2X1, P2X4, P2X7, 
P2Y1, P2Y2, and P2Y6 by siRNAs (Fig. S5, A–F). Depletion 
of P2Y2 consistently resulted in the strongest reduction in 
Figure 4.  Role of P2Y2 in HIV-1 infection. 
(A–D) Detection of P2Y2 (pink, A–C; red, D) 
during the interaction between HIV-1– 
infected lymphoblasts (green) and uninfected 
lymphoblasts, as visualized by confocal micros-
copy. The inset in B represents a yz optical 
section and shows the circular distribution of 
P2Y2. Contrast phase in A and B revealed inter-
acting lymphoblasts. 3D projection (C) and 3D 
reconstruction (D) of merged images unraveled 
a ring-like distribution of P2Y2 between inter-
acting lymphoblasts (bars, 5 µm). (E) Detection 
of P2Y2 on virological synapse mediated by 
HIV-1 envelope between interacting lympho-
blasts. Note the colocalization between P2Y2 
(in red) and the HIV-1 envelope glycoprotein 
gp41 (in green) between HIV-1–infected lym-
phoblasts (in blue) and uninfected lympho-
blasts (arrowhead). Representative micrographs 
of xy (bar, 5 µm), xz (bar, 4 µm), and yz (bar,  
1 µm) optical sections are shown. Images in  
A–E are representative of at least four indepen-
dent experiments. (F) Frequency of P2Y2 polar-
ization at the virological synapse induced by 
HIV-1 between lymphoblasts. Data in F are 
means ± SEM of three independent experi-
ments (*, P < 0.05). (G) Lymphocytic T CEM cells 
were infected during 6 d with HIVNL43 (MOI = 1) 
in the presence of different concentrations of 
the P2Y2 receptor antagonist kaempferol. Cell 
survival and p24 release were measured.  
Error bars indicate SD of three independent 
determinations (*, P < 0.01; **, P < 0.001).  
(H) CD4+CXCR4+ cells expressing Tat-inducible 
-gal reporter gene were infected with HIVNL43 
(MOI = 1) during 3 h in the presence of differ-
ent kaempferol concentrations. 42 h after infection, the percentage of infected target cells was determined by -Gal detection (mean ± SEM; n = 3; **, P < 0.001). 
(I) Effects of kaempferol on Env-induced hemifusion and fusion were determined after 24-h co-culture of CD4+CXCR4+ cells with Env+ cells (means ± SD; 
 n = 3; *, P < 0.01; **, P < 0.001). (J) Representative flow cytometric analysis of intracellular p24 antigen in HIVNDK-infected CEM cells previously transduced 
with lentiviruses encoding indicated shRNA constructs. Representative profiles of three independent experiments are shown. (K) Cells were treated as in J and 
intracellular p24 and p24 release into the supernatant were determined (mean ± SD; n = 3; *, P < 0.01). ND, not detectable. P2Y2 expression by shRNA-trans-
duced clones was evaluated by immunoblotting (inset). (L) CD4+CXCR4+ cells expressing Tat-inducible -gal reporter gene were transfected during 48 h with 
siRNAs specific for P2Y2 or control siRNA and infected with HIVNL43 (MOI = 1). Then, target cell infectivity was determined (means ± SD; n = 3; *, P < 0.01). 
Insets show representative immunoblots of three independent experiments. (M) CD4+CXCR4+ cells were transfected with siRNA as in L. After 24 h of co- 
culture with HIV-1 Env+ cells, hemifusion and fusion induced by HIV-1 envelope were determined (means ± SD; n = 3; *, P < 0.01). (N) CD4+CXCR4+ cells ex-
pressing Tat-inducible -gal reporter gene were transfected with the indicated siRNA and with the wild-type P2Y2 or the P2Y2/4A mutant. Cell fusion 
mediated by the HIV-1 envelope was then evaluated by determining -Gal activity during co-culture with HIV-1 Env+ (mean ± SEM; n = 3; *, P < 0.01).1828 ATP release boosts HIV-1 infectivity | Séror et al.
receptor antagonists (Fig. 5 E). To assess the involvement of 
P2Y2 in this event, we transfected CD4+CXCR4+ with a 
nonmutated P2Y2 cDNA (or as a control with the nonfunc-
tional P2Y2/4A mutant) and observed that overexpression of 
functional P2Y2 increased the plasma membrane depolarization 
of CD4+CXCR4+ cells co-cultured with Env+ cells (Fig. 5 F). 
Conversely, depletion of P2Y2 reduced HIV-1 Env–mediated 
plasma membrane depolarization (Fig. 5 F). These results 
demonstrate that the Src homology domain 3 binding sites 
(PxxP) of P2Y2 (which is mutated in the carboxy-terminal 
tail of P2Y2/4A) is required for plasma membrane depolar-
ization and contributes to Env-dependent fusion events.
P2Y2-dependent activation of proline-rich tyrosine kinase 2 
(Pyk2) is required for HIV-1 infection
P2Y2 (but not its mutant P2Y2/4A, see previous section) 
participates in the formation of a polyprotein complex that 
activates Pyk2 (Seye et al., 2004). We found that the activating 
phosphorylation or autophosphorylation on tyrosine residue 
402 of Pyk2 (Pyk2Y402*) increased after P2Y2 overexpres-
sion during infection of human PBMCs with HIV-1 (Fig. 6 A) 
and during the formation of conjugates between Env+ and 
CD4+CXCR4+ HeLa cells (Fig. S7  A). Pyk2Y402* overexpres-
sion was mainly detected in HIV-1–infected cells (Fig. S7 B). 
Moreover, Pyk2Y402* was enriched in ring-like structures at 
the contact site between such conjugates (Fig. 6, B and D) 
and between HIV-1–infected lymphoblasts and uninfected 
lymphoblasts (Fig. 6, C and E). In addition, Pyk2Y402* polar-
ization was preferentially observed in uninfected lympho-
blasts  (Fig.  S7  C). The  phosphorylation  of  Pyk2  was  also 
detectable in lymph nodes from untreated HIV-1 carriers 
(Fig. 6, F and H), in the frontal cortex from patients with 
HIV-associated encephalitis (HAE; Fig. 6, G and I), and in 
circulating leukocytes from HIV-1 carriers, correlating with 
viral load (Fig. 6 J). Approximately 40% of CD3+CD4, 60% 
of CD4+, and 15% of CD19+ cells obtained from PBMCs re-
vealed the activating phosphorylation of Pyk2 after in vitro 
revealed the polarization of P2Y2 at the contact site between 
HIV-1–infected  and  uninfected  lymphoblasts  (Fig.  4, A–F; 
and Fig. S6, B–D). P2Y2 distributed to ring-like structures 
(Fig. 4, B–E; and Fig. S6 E) that also contained the HIV-1 
glycoprotein gp41 (Fig. 4 E) and the co-receptor CD4 (not 
depicted), indicating that P2Y2 accumulated at the virological 
synapse that is formed between HIV-1–infected and uninfected 
lymphoblasts. This P2Y2 polarization was observed preferen-
tially in uninfected cells (Fig. 4 F and Fig. S6 E). Pharmaco-
logical  P2Y2  inhibition  with  kaempferol  (Kaulich  et  al.,   
2003; Fig. 4, G–I; and Fig. S6, F–H) or knockdown of P2Y2   
(Fig. 4, J–M; and Fig. S6 I) reduced HIV-1–associated cell 
death (Fig. 4 G), HIV-1 infection (Fig. 4, G–L), and Env- 
mediated hemifusion and fusion (Fig. 4, I and M; and Fig. S6, 
G and H), suggesting that P2Y2 controls HIV-1 infection.   
Indeed,  the  transfection-enforced  overexpression  of  P2Y2   
increased the fusion between Env+ and CD4+CXCR4+ cells 
(Fig. 4 N). In addition, the fusion-inhibitory effect of a P2Y2-
specific siRNA was overcome by transfection with a non-
interferable P2Y2 cDNA but not with a nonfunctional P2Y2 
mutant, P2Y2/4A (Seye et al., 2004), underscoring the contribu-
tion of this purinergic receptor to HIV-1 infection (Fig. 4 N).
P2Y2 triggers plasma membrane depolarization to allow 
HIV-1 infection
Infection with HIV-1 is associated with a transient depolar-
ization of the plasma membrane (Melikyan, 2008; Fig. 5 A). 
Transient abolition of the plasma membrane K+ gradient by 
culturing cells in a medium containing 70 mM KCl for 3 h 
strongly induced membrane depolarization (Fig. 5, B and C) 
and enhanced the fusion of Env+ and CD4+CXCR4+ cells 
that was reduced in the presence of the CXCR4 antagonist 
AMD3100 (Fig. 5 D), demonstrating that plasma membrane 
depolarization of HIV-1 target cells is required for Env- 
dependent fusion events. Plasma membrane depolarization 
induced by HIV-1 infection was abolished by addition of 
AMD3100, ATP-depleting  apyrase,  or  several  purinergic   
Figure 5.  P2Y2 controls plasma membrane depolarization 
during HIV-1 Env–mediated fusion. (A) Plasma membrane 
depolarization of primary lymphoblasts 1 h after infection with 
HIVNDK (MOI = 1) was determined by evaluating the increase of 
fluorescence of DiBac4(3) probe by flow cytometry. Representa-
tive profiles of three independent experiments are shown.  
(B) CD4+CXCR4+ cells were treated with 70 mM KCl or control 
for 3 h. Plasma membrane depolarization was determined by 
evaluating the increase of fluorescence of the DiBac4(3) probe. 
Representative profiles of three independent experiments are 
shown. (C) Frequency of plasma membrane depolarized 
CD4+CXCR4+ cells after 3 h of 70 mM KCl treatment (mean ± 
SEM; n = 3; *, P < 0.05). (D) Effects of 5 µM AMD3100 on HIV-1 
Env–induced fusion in the absence or presence of 70 mM KCl. 
The error bars represent means ± SEM (n = 3; *, P < 0.05).  
(E) Effects of AMD3100, apyrase, PPADS, and OxATP on plasma 
membrane depolarization after 1 h of HIVNDK infection. Results were obtained in three independent experiments (mean ± SEM; *, P < 0.05) using the  
DiBac4(3) probe and flow cytometry. (F) Effects of transfections of human P2Y2 wild-type (P2Y2), P2Y2 mutant (P2Y2/4A) constructs, and siRNA against 
P2Y2 (siRNA-1 P2Y2) on HIV-1 envelope–induced plasma membrane depolarization were determined as described in A (mean ± SEM; n = 3; *, P < 0.05).JEM Vol. 208, No. 9 
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and p24 antigen release (Fig. 6 O), and Pyk2 knockdown   
inhibited HIV-1 infection, as well as Env-mediated hemifusion 
and fusion (Fig. 6 P). Collectively, these results indicate that 
Pyk2 is a critical effector of HIV-1 infection, operating down-
stream of P2Y2.
Depletion of each of the protein components of the hy-
pothetical  cascade  delineated  in  this  paper  (pannexin-1→
ATP→P2Y2→Pyk2) reduced infection by standard HIV-1 
isolates (Fig. 1, B, I, and J; Fig. 4, J–L; and Fig. 6, N–P) as well 
as by viruses that had been rendered resistant against reverse 
transcription and integrase inhibitors by selective point muta-
tions (Bacheler et al., 2000; Delelis et al., 2009; Fig. 7 A).   
HIV-1 infection (Fig. S7 D). In addition, the vast majority of 
syncytia detected in lymph nodes from untreated HIV-1 car-
riers or in the frontal cortex from patients with HAE were 
positive for Pyk2Y402* (Fig. S7 E). Highly active antiretro-
viral therapy reduced immunodetectable Pyk2Y402* in PBMC 
from HIV-1–infected donors (Fig. 6 K). Depletion of P2Y2 
reduced the phosphorylation of Pyk2 (Fig. S7 A) and inhib-
ited the polarization of Pyk2Y402* at the contact sites be-
tween cocultured Env+ and CD4+CXCR4+ cells (Fig. 6 L) or 
between HIV-1–infected and uninfected target cells (Fig. 6 M 
and Fig. S7 F). Pyk2 depletion before HIV-1 infection simi-
larly decreased intracellular p24 (Fig. 6, N and O; and Fig. S7 G) 
Figure 6.  P2Y2 induces Pyk2 activation 
during HIV-1 infection. (A) PHA+IL-2– 
stimulated human PBMCs were infected with 
HIVNDK (MOI = 1) for the indicated periods. 
Pyk2Y402* and Pyk2 expression were deter-
mined by immunoblotting. GAPDH expression 
was used as loading control. Representative 
immunoblots of three independent experi-
ments are shown. (B) Representative 
Pyk2Y402* polarization (red) between HIV 
Env+ cells (green) and CD4+CXCR4+ cells was 
analyzed by confocal microscopy (bar, 5 µm). 
The inset in B shows the yz section (bar, 3 
µm). (C) Detection of Pyk2Y402* (pink) polar-
ization during interaction between HIV-1–
infected lymphoblasts (green) and uninfected 
lymphoblasts by confocal microscopy (bar,  
5 µm). The left inset represents an xz optical 
section and polarization of Pyk2Y402* be-
tween interacting cells (bar, 4 µm). The right 
inset corresponds to a yz optical section and 
shows peripheral distribution of Pyk2Y402* in 
the contact site within conjugates (bar, 3 
µm). Images are representative of four inde-
pendent experiments. (D and E) Frequency of 
Pyk2Y402* polarization between single cells 
and conjugates during co-culture of HIV Env+ 
cells and CD4+CXCR4+ cells (D) or co-culture 
of HIV-1–infected lymphoblasts and unin-
fected lymphoblasts (E) was determined in 
three independent experiments (mean ± SEM; 
*, P < 0.05). (F–I) Detection of Pyk2Y402* in 
lymph node sections (F and H) and frontal 
cortex biopsies (G and I) obtained from HIV-
1–infected and uninfected patients (HIV-1–
infected bar, 50 µm; HIV-1 uninfected bar,  
25 µm). The percentage of Pyk2Y402*+ cells found in lymph node (H) and frontal cortex biopsies (I) was quantified. Error bars represent means ± SEM (*, P < 0.01; 
n = 5). (J) Correlation between Pyk2Y402* detected on PBMCs and viremia obtained from untreated HIV-1 carriers. The p-value corresponds to the  
correlation coefficient. (K) Effect of HAART on Pyk2Y402* detected on PBMCs obtained from treated patients, as compared with untreated HIV-1–infected 
donors (mean ± SEM; *, P = 0.0009). (L and M) Effects of P2Y2 knockdown on Pyk2Y402* polarization at the contact site between conjugates during  
co-culture of HIV Env+ cells and CD4+CXCR4+ cells (L) or co-culture of HIV-1–infected T CEM cells and uninfected P2Y2-depleted T CEM cells (M), as 
determined by confocal microscopy in three independent experiments (mean ± SEM; *, P < 0.01). (N and O) Effects of Pyk2 depletion on intracellular 
p24 (N and O) and p24 antigen release (O), as determined by immunofluorescence staining and ELISA, respectively. The indicated parameters were mea-
sured after HIVNDK infection of CEM clones transduced with shRNAs specific for Pyk2, 6 d after infection. Representative FACS profiles of three indepen-
dent experiments are shown in N and quantitative results (mean ± SD; n = 3; *, P < 0.01) are shown in O. (P) Effects of Pyk2 knockdowns on HIVNL43WT 
infection, hemifusion, and fusion induced by HIV-1 envelope (mean ± SEM; n = 3; *, P < 0.05). The knockdown of Pyk2 by two nonoverlapping siRNAs 
was confirmed by Western blot (inset).1830 ATP release boosts HIV-1 infectivity | Séror et al.
Thus,  a  recent  study  revealed  that  OppA,  the  substrate- 
binding  domain  of  Mycoplasma  hominis  permease  increases   
the  microbe’s  extracellular  survival  by  inducing  release  of 
ATP from host cells (Hopfe and Henrich, 2008). In addition, 
treatment of Mycobacterium avium–infected cells with apyrase 
decreased intracellular survival of the pathogens (Woo et al., 
2007). Our results differ from these studies in that they dem-
onstrate that extracellular ATP released by HIV-1 host cells 
favors the initial steps of HIV-1 infection. Thus, ATP that is 
rapidly released during the infectious process from HIV-1   
target cells does not only act as a danger signal but also con-
tributes to viral uptake.
In this paper, we report the identification of proteins in-
volved in HIV-1–induced ATP release and in ATP-mediated 
signaling events that contribute to viral infection. Thus, we 
identified several novel proteins that are required for efficient 
HIV-1 infection of CD4+ host cells and showed that HIV-1 
can stimulate ATP release into the extracellular milieu through 
pannexin-1 hemichannels, perhaps as a result of mechanical 
stress of the host cell membrane (Bao et al., 2004). ATP then 
acts in an autocrine and paracrine fashion to activate puri-
nergic receptors, in particular P2Y2, a seven-transmembrane- 
anchored G protein–coupled receptor that can induce the 
phosphorylation/recruitment of the proline/tyrosine kinase 
Pyk2 (Liu et al., 2004). Indeed, pannexin-1, P2Y2, and Pyk2 
were all recruited to the contact site between Env-containing 
and CD4/CXCR4-containing membranes, suggesting that 
they act within the virological synapse to transduce signals 
that enhance membrane-to-membrane fusion, participate in 
the infectious process, and facilitate viral cell-to-cell transmis-
sion (Fig. 7 E; Jolly et al., 2007; Hübner et al., 2009).
Similarly, purinergic receptor antagonists were able to inhibit 
infection by genetically engineered therapy-resistant HIV-1 
mutants (Fig. 7 B) and tritherapy-selected viruses (Fig. 7 C), 
consistent  with  the  possibility  that  inhibition  of  the  pan-
nexin-1→ATP→P2Y2→Pyk2 cascade can mediate antiretro-
viral effects under conditions in which conventional therapy 
fails. In addition, purinergic receptor antagonists reduced the 
death of activated CD4+ T lymphoblasts infected by HIV-1 
(Fig. 7 D), suggesting that interruption of P2Y2 signaling 
confers immunoprotective effects.
DISCUSSION
Although many early steps of infectious processes are associ-
ated with host membrane alterations, there are no studies that 
evaluate whether extracellular nucleotides might impact on 
the viral life cycle. In this paper, we show that ATP is released 
into the extracellular milieu during the early steps of HIV-1 
infection and that this extracellular ATP is required for effi-
cient viral uptake. During the initial stages of the infectious 
process, ATP release may determine viral clearance or the persis-
tence of the infection by effects on the immune system. Massive 
ATP release during infection reportedly can deliver a danger 
signal to immune effectors. Thus, extracellular ATP may acti-
vate the inflammasome, which participates in the caspase-1–
dependent maturation and secretion of the proinflammatory 
cytokines IL-1, IL-18, and IL-33 (Schroder and Tschopp, 
2010)  or  stimulate  neutrophil  migration  and  phagocytosis 
(Chen et al., 2006). Moreover, extracellular ATP can favor the 
killing of some intracellular pathogens (Lammas et al., 1997; 
Coutinho-Silva et al., 2003) or, on the contrary, promote the 
survival of other infectious agents (Corriden and Insel, 2010). 
Figure 7.  Inhibition of pannexin-1, 
P2Y2, and Pyk2 reduces HIV-1 infectivity 
and T cell depletion associated with HIV-1 
infection. (A) Effects of pannexin-1, P2Y2, 
and Pyk2 siRNA on the infectious activity of 
therapy-resistant HIV-1 mutated viruses 
(HIVNL43RTK103N and HIVNL43IN140:148). Target cell 
infectivity was determined using CD4+CXCR4+ 
cells expressing Tat-inducible -Gal reporter 
gene. Results are representative of three inde-
pendent experiments (mean ± SEM; *, P < 
0.01). (B) Effects of different concentrations 
of suramin, PPADS, and OxATP on HIV mutant 
infectivity, as determined in A. (C) PH2+IL-2–
stimulated PBMCs obtained from HAART-
treated patients (with undetectable viremia) 
were treated with 100 µM suramin, 100 µM 
PPADS, and 100 µM OxATP. Then, p24 antigen 
release was determined after 1, 3, and 7 d of 
infection. Results shown are representative of 
three HAART-treated patients. (D) HIVNDK-infected PHA+IL-2–stimulated lymphoblasts were treated with 5 µM AMD3100, 100 µM suramin, or 100 µM 
PPADS. 7-AAD uptake (analyzed by flow cytometry) and intracellular p24 antigen expression (measured by flow cytometry) were assessed. Results were 
pooled from three independent experiments (mean ± SEM; *, P < 0.01). (E) Involvement of pannexin-1, ATP release, P2Y2 activation, and Pyk2Y402*  
phosphorylation in early stages of HIV-1 infection. Binding of HIV-1 envelope to cellular receptors leads to rapid ATP release from host cells through  
pannexin-1. ATP then activates P2Y2 receptors, leading to activation (phosphorylation) of Pyk2 (Pyk2Y402*). P2Y2 and Pyk2 control plasma membrane 
depolarization, hemifusion, and fusion, which are required for HIV-1 infection.JEM Vol. 208, No. 9 
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MATERIALS AND METHODS
Cells and culture conditions. PBMCs were isolated from the blood of 
normal volunteers (Etablissement Français du Sang [EFS] Cabanel, Paris, 
France) over a Ficoll-Hypaque density gradient. Blood was obtained through 
the EFS in the setting of EFS-Institut Pasteur Convention. A written in-
formed consent was obtained for each donor to use the cells for clinical re-
search  in  compliance  with  French  Law  and  the  Biomedical  Research 
Committee Board from Institut Pasteur (Paris, France). CD14+ monocytes 
were  isolated  from  PBMC  by  positive  selection  using  anti-CD14  beads 
(Miltenyi  Biotec). To  generate  monocyte-derived  macrophages  (MDMs),   
purified monocytes were incubated in RPMI 1640 medium supplemented 
with 100 U/ml penicillin–100 µg/ml streptomycin (Invitrogen) and 10% 
FCS in the presence of 10 ng/ml recombinant human (rh) M-CSF (Pepro 
Tech). After 6 d of culture, adherent cells corresponding to the macrophage-
enriched fraction were harvested, washed, and used for subsequent experi-
ments. To generate monocyte-derived DCs (MDDCs), purified monocytes 
were cultured in RPMI 1640 medium supplemented with 10% antibiotics 
and FCS. Cultures were maintained for 6 d in 24-well trays (106 cells/well) 
supplemented with 10 ng/ml rhGM-CSF (PeproTech) and rhIL-4 (PeproTech). 
The  medium  was  replaced  every  2  d. After  6  d  of  culture,  MDDCs   
were semi-adherent cells and expressed high levels of DC-SIGN but not 
monocyte/macrophage markers such as CD14 and CD16. Flow cytometry 
analysis (CellQuest software; BD) demonstrated that MDMs and MDDCs 
were >90% pure. T cells were subsequently prepared from the monocyte- 
depleted cell fractions. PBLs were cultured for 48 h in fresh medium supple-
mented with 2.5 µg/ml PHA (Sigma-Aldrich) and 1 µg/ml rhIL-2 (PeproTech). 
PBLs were then washed and cultured in growth medium containing 1 µg/ml 
rhIL-2 for 24 h. These cells were infected with HIV-1 during 3 d with a 
multiplicity of infection (MOI) of 1, as previously described (Saïdi et al., 
2008; Melki et al., 2010). HeLa cells stably transfected with the Env gene of 
HIV-1 LAI/IIIB (HeLa Env) and HeLa cells transfected with CD4 (HeLa 
CD4) were cultured alone or together at a 1:1 ratio in Dulbecco’s modified 
Eagle’s medium supplemented with 10% FCS, 2 mM l-glutamine, and 100 
UI/ml penicillin/streptomycin (Invitrogen) in the absence or in presence of 
tested molecules. CEM T lymphocytes were maintained in RPMI 1640   
medium containing 10% FCS, 2 mM l-glutamine, and 100 UI/ml penicillin/ 
streptomycin (Invitrogen).
Viral and pseudo-viral constructs. Viral stocks of wild-type X4, R5, and 
resistant HIV-1 were obtained after transfection of 293T with virus encoding 
plasmids as previously described (Perfettini et al., 2008; Delelis et al., 2009). 
The standardization of HIV-1 infection was achieved by means of the Alli-
ance HIV-1 P24 antigen ELISA assay (PerkinElmer) and infection of P4 cells 
followed  by  fixation  and  determination  of  -galactosidase  activity. Viral 
RNA and DNA and viral production were analyzed, as previously described 
(Delelis et al., 2009).
Pharmacological  inhibitions.  Primary  human  lymphoblasts,  MDMs, 
MDDCs, lymphocytic CEM cells, or CD4+CXCR4+ target cells were seeded 
into 96-well culture plates (1–2 × 104 cells /well) and incubated 30 min with 
increasing concentrations of apyrase, CXCR4 antagonist (AMD3100), the 
P2 receptor antagonist suramin, the P2X-selective antagonist OxATP, the 
P2Y-selective antagonist PPADS, carbenoxolone (CBX), DIDS, and SITS. 
Then, cells were incubated with wild-type HIV-1, VSV-pseudotyped HIV-1, 
therapy-resistant HIV-1 mutated viruses (1 ng of p24 antigen), or clinical HIV-1 
isolates (15 ng of p24 antigen) for 3 h at 37°C in a 5% CO2 atmosphere. After 
washing out unabsorbed virus, cells were cultured for the indicated times in 
the presence of tested molecules. The absolute number of total remaining   
viable cells and cell death were analyzed, as previously described (Lecoeur   
et al., 2002; Melki et al., 2010). Apyrase, AMD3100, ATP, ATP-S, suramin, 
PPADS, OxATP, CBX, DIDS, and SITS were purchased from Sigma-Aldrich.
RNA interference. siRNAs specific for pannexin-1 (siRNA-1, 5-GCUC-
CAAGGUAUGAACAUA-3;  siRNA-2,  5-ACGAUUUGAGCCUC-
UACAA-3), CD4 (siRNA, 5-ACUGAGGAGUCUCUUGAUC-3), 
At present, the exact mechanisms by which P2Y2 modu-
lates HIV-1 infection remain elusive. However, we found that 
after the interaction between HIV-1 envelope and its co- 
receptors, P2Y2 was activated and could directly interact with 
filamin A, a modulator of the actin cytoskeleton involved   
in the formation of stable receptor–co-receptor complexes   
(Jiménez-Baranda  et  al.,  2007).  P2Y2  can  also  indirectly, 
through its SH3 binding (PxxP) site, control the phosphory-
lation of Pyk2 on tyrosine 402 (Liu et al., 2004), and this 
event  might  induce  its  phosphorylation/relocation  to  the   
virological synapse. Pyk2 regulates multiple signaling events 
that participate in the reorganization of the actin cytoskeleton 
and contribute to macrophage polarization and migration in 
response to chemokine stimulation (Okigaki et al., 2003). Pyk2 
can control HIV-1 Env–mediated fusion (Harmon and Ratner, 
2008). During HIV-1 infection, Pyk2 is phosphorylated after 
interactions  between  distinct  Env  variants  (from  X4-  and 
R5-tropic strains) and Env receptors on HIV-1 target cells 
(CD4 and chemokine receptors; Davis et al., 1997). The   
activating phosphorylation or autophosphorylation of Pyk2 
(Pyk2Y402*) that we detected during HIV-1 infection in vitro 
and in vivo might be induced in response to chemokine stim-
ulation or elevations of intracellular Ca2+ concentrations (Lev 
et al., 1995). Activated Pyk2 then may modulate the forma-
tion of a signaling complex that contains Src family kinases 
and actin interacting proteins (Block et al., 2010). In this paper, 
we identified the ATP-mediated stimulation of the puriner-
gic  receptor  P2Y2  as  an  upstream  event  required  for  the 
phosphorylation of Pyk2 (Pyk2Y402*). P2Y2 activation is 
known  to  modulate  Ca2+  influx  after  nucleotide  binding 
(Ralevic and Burnstock, 1998) and may also regulate Pyk2 
activities by recruiting it into a polyprotein complex that also 
contains the tyrosine kinase Src (Seye et al., 2004). Although 
we demonstrated that P2Y2 activation induced Pyk2Y402*, 
the precise mechanisms linking P2Y2 activation and polariza-
tion/phosphorylation of Pyk2 remain elusive. Moreover, future 
investigations must explore how plasma membrane depolar-
ization, which is essential for HIV-1 infection, results from   
the activation of P2Y2 and Pyk2.
Inhibition of any of the constituents of the molecular cascade 
that we delineated in this study (pannexin-1→ATP→P2Y2→
Pyk2) could interrupt the HIV-1 life cycle at the level of viral 
entry. Thus,  inhibition  of  pannexin  hemichannels,  enzymatic   
depletion of extracellular ATP, antagonizing P2Y2 receptors, or 
suppression of Pyk2 kinase activity could constitute effective 
strategies for the blockade of HIV-1 infection, be it locally (for 
instance by application of topical gels) or systemically (ideally 
with orally available drugs). The toxicology of some putative 
therapeutic agents acting on this cascade (such as apyrase) is satis-
factory (Marcus et al., 2005), whereas that of others (such as sura-
min) is not (Grossman et al., 2001), underlining the need for the 
development of highly specific inhibitors against pannexin-1, 
P2Y2, and Pyk2. Beyond these clinical considerations, it will be 
important to investigate whether any or all of the constituents of 
the pannexin-1→ATP→P2Y2→Pyk2 pathway may participate 
in host cell infection by HIV-1–unrelated viruses.1832 ATP release boosts HIV-1 infectivity | Séror et al.
PCR included initial denaturation at 95°C for 10 min, followed by 40 cycles 
at 95°C for 30 s, 55°C for 1 min, and 72°C for 1 min, and one cycle at 95°C 
for 1 min, 55°C for 30 s, and 95°C for 30 s. The CT values were normalized 
to the housekeeping gene GAPDH.
Immunoblots, immunofluorescence, and flow cytometry. Total cellular 
proteins were extracted in 250-mM NaCl-containing lysis buffer (250 mM 
NaCl, 0.1% NP-40, 5 mM EDTA, 10 mM Na3VO4, 10 mM NaF, 5 mM 
DTT, 3 mM Na4P2O7, and the protease inhibitor cocktail [EDTA-free pro-
tease inhibitor tablets; Roche]). 50 µg of protein extracts were run on 4–12% 
SDS-PAGE and transferred at 4°C onto a nitrocellulose membrane. After 
blocking, membranes were incubated with primary antibody at room tem-
perature overnight. Horseradish peroxidase–conjugated goat anti–mouse or 
anti–rabbit (SouthernBiotech) antibodies were then incubated for 1 h and 
revealed with the enhanced ECL detection system. After 3 d of infection 
with HIVNDK (MOI = 1), PHA/IL-2–stimulated peripheral blood lympho-
cytes were stained with 10 µM 5-chloromethylfluorescein diacetate (Cell 
Tracker green; CMFDA; Invitrogen) and cocultured with uninfected lym-
phoblasts for 48 h. Cells were then fixed in 4% paraformaldehyde/PBS for   
30 min, permeabilized in 0.1% SDS in PBS, and incubated with FCS for   
20 min, as previously described (Perfettini et al., 2004). Polyclonal rabbit anti-
bodies for the detection of P2Y2 were purchased from Abcam or Alomone 
laboratories. Polyclonal rabbit antibodies against pannexin-1 were obtained 
from Abcam and Millipore. The polyclonal rabbit antibodies used for the de-
tection  of  Pyk2  and  the  phosphorylated  form  of  Pyk2  on  tyrosine  402 
(Pyk2Y402*) were obtained from Cell Signaling Technology. The monoclo-
nal mouse antibody against HIV-1 gp41 (50–69) was obtained from National 
Institutes of Health AIDS Research and Reference Reagent Program (Bethesda, 
MD). Antisera were used for immunodetection in PBS containing 1 mg/ml BSA 
and revealed with goat anti–rabbit IgG conjugated to Alexa Fluor 546 fluoro-
chromes from Invitrogen. Actin was also stained using an Alexa Fluor 647 (or 
488)–conjugated phalloidin depending on the experiment. Cells were analyzed 
by fluorescent confocal microscopy on an LSM510 (Carl Zeiss) using a 63× 
objective. Z series of optical sections at 0.2-µm increments were acquired. After 
image deconvolution, 3 D image reconstructions of interacting cells were   
performed using the IsoSurface function of Imaris 5.7 Software (Bitplane AG).   
Phenotypic analyses were realized by flow cytometry as previously described 
(Melki et al., 2010), and we used the monoclonal mouse antibody against HIV-1 
p24 (KC57) conjugated to FITC (Beckman Coulter), the monoclonal mouse anti-
bodies against CD3 or CD4 conjugated to FITC or to peridinin chlorophyll 
protein complex (PerCP; BD), and the monoclonal mouse antibody against 
CD19 conjugated to allophycocyanin (Miltenyi Biotech).
Measurement of extracellular ATP. ATP release during co-cultures or 
infection with HIV-1 were determined using the Enliten ATP assay system 
(Promega) as described by the manufacturer. The luminescence was mea-
sured by integration over a 3-s time interval using the luminometer Fluostar 
OPTIMA (BMG Labtech).
Hemifusion and cell–cell fusion assays. HeLa Env+ and HeLa CD4+CXCR4+ 
cells were, respectively stained for hemifusion analysis with 1 µM 1,1-diocta-
decyl-3,3,3,3-tetramethylindocarbocyanine perchlorate (DiIC18(3), Invitrogen) 
and 10 µM 5-chloromethylfluorescein diacetate (Cell Tracker green; CMFDA) 
or for cell–cell fusion analysis, respectively, with 10 µM 5-chloromethylfluores-
cein diacetate (Cell Tracker green; CMFDA) and 10 µM 5-,6-,4-chloromethyl-
benzoyl aminotetramethyl rhodamine (Cell Tracker orange; CMTMR; 
Invitrogen). Cells were then cultured alone or together for 24 h, at a 1:1 ratio 
in Dulbecco’s modified Eagle’s medium supplemented with 10% FCS, 2 mM 
l-glutamine, and penicillin/streptomycin (Invitrogen) in the absence or pres-
ence of the indicated concentrations of purinergic receptor inhibitors. The   
effects of these inhibitors on hemifusion and cell–cell fusion mediated by the 
HIV-1 envelope were evaluated by fluorescence microscopy.
Measurement of target cell infectability. HeLa cells stably transfected 
with CD4, as well as the LacZ gene under the control of the HIV-1 LTR 
(HeLa-CD4), were selected in medium containing 500 µg/ml G418. Target 
P2X1  (siRNA,  5-GUGGCAGUCAGUAACCAUA-3),  P2X4  (siRNA, 
5-GGAAAACUCCCUCUUCGUC-3), P2X7 (siRNA, 5-GCUGUCG-
CUCCCAUAUUUA-3), P2Y1 (siRNA, 5-AUUAUCACCAGGUAAAUG-
GAUUUCC-3), P2Y2 (siRNA-1, 5-GGAUAGAAGAUGUGUUGGG-3; 
siRNA-2, 5-GGCUGUAACUUAUACUAAA-3), P2Y6 (siRNA, 5-GG-
UGCUCACAAAAAUACA-3), PYK2 (siRNA-1, 5-GCUGAUCGGCAU-
CAUUGAA-3;  siRNA-2,  5-GGCGGUUCUUCAAGGAUAU-3),  and 
control sirRNA (5-GCCGGUAUGCCGGUUAAGU-3) were trans-
fected 48 h before HIV-1 infection or cell fusion using Oligofectamine 
(Invitrogen), according to the manufacturer’s instructions. For short hair-
pin RNA (shRNA) lentiviral particle transduction, the pRS shRNA ex-
pression retroviral vector coding for each targeted gene was purchased from   
Origene. Oncovirus vector particles were generated by cotransfection of 
three plasmids coding for the gag-pol genes from moloney mouse leukemia 
virus (pUMVC3-gag-pol; University of Michigan), for the vector genome 
carrying your shRNA of interest (pRS shRNA), and for the plasmid cod-
ing for an envelope of VSV (pMDG; Tronolab). Cotransfection was effected 
into 293T cells (human embryonic kidney cell) using superFect transfection 
reagent (QIAGEN) according to the manufacturer’s protocol.
On day 2 after transfection, supernatants were filtered (0.45-µm cellu-
lose acetate filters; Sartorius Stedim), aliquoted, and frozen at 80°C. For 
transduction, oncovirus aliquots were added to T lymphocytic CEM-T4 cell 
line, and 24 h after infection the medium was replaced with fresh growth 
medium containing 1 µg/ml puromycin (Cayla). Clonal populations were 
obtained by transferring single cells into U-bottom 96-well plates and by 
maintaining selection pressure for 3 wk. Silencing of proteins was deter-
mined by quantitative RT-PCR and/or by Western blotting.
Quantitative real-time RT-PCR. mRNA was isolated from cells after the   
indicated treatments using the RNeasy kit (QIAGEN) according to the man-
ufacturer’s instructions, and total RNA was converted into cDNA by stan-
dard reverse transcription with the TaqMan reverse transcription kit (Applied 
Biosystems). Quantitative PCR were performed with the cDNA preparation 
(1:50) in the Mx3000P system (Agilent Technologies) in a 25-µl final volume 
with Brilliant QPCR Master Mix (Agilent Technologies). The primers for 
human for human Panx-1 were 5-GGTGAGACAAGACCCAGAGC-3 
(forward) and 5-GGCATCGGACCTTACACCTA-3 (reverse). The prim-
ers  for  human  P2X1  were  5-GCTGGTGCGTAATAAGAAGGTG-3  
(forward)  and  5-ATGAGGCCGCTCGAGGTCTG-3  (reverse). The   
primers for human P2X4 were 5-GATACCAGCTCAGGAGGAAAAC-3 
(forward) and 5-GCATCATAAATGCACGACTTGAG-3 (reverse). The 
primers for human P2X7 were 5-TGATAAAAGTCTTCGGGATCCGT-3 
(forward)  and  5-TGGACAAATCTGTGAAGTCCATC-3  (reverse). The 
primers for human P2Y1 were 5-CTTGGTGCTGATTCTGGGCTG-3  
(forward)  and  5-GCTCGGGAGAGTCTCCTTCTG-3  (reverse).  The   
primers for human P2Y2 were 5-CCGCTCGCTGGACCTCAGCTG-3 
(forward)  and  5-CTCACTGCTGCCCAACACATC-3  (reverse). The 
primers for human P2Y4 were 5-CGCTGCCCACCCTCATCTAC-3 
(forward)  and  5-CCGAGTGGTGTCATGGCACAG-3  (reverse).  The 
primers for human P2Y5 were 5-TGTTCAGTCTACCCACTCTCAG-3 
(forward)  and  5-CTTACTGCTGCCACTACTGAGC-3  (reverse).  The 
primers for human P2Y6 were 5-AACCTTGCTCTGGCTGACCTG-3 
(forward) and 5-GCAGGCACTGGGTTGTCACG-3 (reverse). The prim-
ers  for  human  P2Y8  were  5-CTCCTGGCGCACATCGTGAG-3  
(forward)  and  5-GGAGCGCACGGACGTGGTC-3  (reverse).  The 
primers for human P2Y10 were 5-GGTGTTCATGTGTGCTGCAGTC-3 
(forward)  and  5-ATGGCGGGATAGTTGGTCACG-3  (reverse).  The   
primers for human P2Y11 were 5-GAGGCCTGCATCAAGTGTCTG-3 
(forward)  and  5-ACGTTGAGCACCCGCATGATG-3  (reverse).  The 
primers for human P2Y12 were 5-ACCGGTCATACGTAAGAACGAG-3 
(forward) and 5-GCAGAATTGGGGCACTTCAGC-3 (reverse). The 
primers for human P2Y13 were 5-GGAAGCAACACCATCGTCTGTG-3 
(forward) and 5-GACTGTGAGTATATGGAACTCTG-3 (reverse) and 
for human GAPDH were 5-CAATGCATCCTGCACCACCAA-3 (for-
ward) and 5-GTCATTGAGAGCAATGCCAGC-3 (reverse). Real-time JEM Vol. 208, No. 9 
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